Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»283610.69541/NRIPH.2024.03.009Обзорная статьяCancer screening in patients at risk for breast cancer under 40 years of age. Literature reviewA. KomissarovaValeria A.lera21734tkd@gmail.comhttps://orcid.org/0000-0002-5862-1761SafontsevIvan P.safoncev@gmail.comhttps://orcid.org/0000-0002-8177-6788ZukovRuslan A.zukov.ra@krasgmu.ruhttps://orcid.org/0000-0002-7210-3020Federal State Budgetary Educational Institution of Higher Education «Prof. V.F.Voino-Yasenetsky Krasnoyarsk State Medical University» of the Ministry of Healthcare of the Russian Federation (FSBEI НЕ Prof. V.F.Voino-Yasenetsky KrasSMU MOH Russia)A.I.Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology DispensaryA.I.Kryzhanovsky Krasnoyarsk Territorial Clinical Oncology Dispensary, Krasnoyarsk, Russia Federation011020243596527052025Copyright © 2025,2025<p>Special attention in this review is paid to risk factors for breast cancer, the features of mammography as the main method of cancer screening for diagnosing breast tumors in the age group of patients subject to preventive and medical examinations. The idea why of standard screening not suitable for young women is highlighted. A comparative analysis of existing mathematical models for assessing individual risk of developing breast cancer was carried out. The advantages and disadvantages of the selected models are noted. Based on the analysis, the need to optimize the approach for the selection of diagnostic tactics based on the assessment of risk factors was identified in order to increase the proportion of early detection of breast pathologies.</p>reviewbreast cancerrisk factorscancer screeningearly detectionобзорвозраст до 40 летрак молочной железыфакторы рискаонкоскринингранняя диагностика[Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute. JNCI. 1989;81(24):1879—1886. DOI: 10.1093/jnci/81.24.1879][Gail MH, Pfeiffer RM. Breast Cancer Risk Model Requirements for Counseling. Journal of the National Cancer Institute. JNCI. 2018;110(9):994—1002. DOI: 10.1093/jnci/djy013][Escala-Garcia M, Morra A, Canisius S et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC medicine. 2020;18:1—10. DOI: 10.1186/s12916-020-01797-2][Bodewes FTH, van Asselt AA, Dorrius MD at al. Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis. The Breast. 2022;66:62—68. DOI: 10.1016/j.breast.2022.09.007][Khoury T, Ademuyiwa FO, Chandrasekhar R et al. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Modern Pathology. 2012;25(3):388—397. DOI: 10.1038/modpathol.2011.172][Bahl M, Gaffney S, McCarthy AN et al. Breast Cancer Characteristics Associated with 2D Digital Mammography versus Digital Breast Tomosynthesis for Screening-detected and Interval. Radiology. 2018;287(1):49—57. DOI: 10.1038/modpathol.2011.172][Vysotskaya I.V. Atypical hyperplasia of the mammary gland. Tumors of the female reproductive system. [Opukholi zhenskoy reproduktivnoy sistemy]. 2015;11(4):10—17 (in Russian).][Wang K, Li F, Chen L et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget. 2018;8(46):81109. DOI: 10.18632/oncotarget.20154][Couch FJ, Shimelis H, Hu C et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA oncology. 2017;3(9):1190—1196. DOI: 10.1001/jamaoncol.2017.0424][Hu C, Hart CH, Gnanaolivu R et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine. N Eng J Med. 2021;384(5):440—451. DOI: 10.1056/NEJMoa2005936][Starek-Świechowicz, B, Budziszewska B, StarekA. Alcohol and breast cancer. Pharmacological Reports. 2023;75(1):69—84. DOI: 10.1007/s43440-022-00426-4][Xu M, Chen G, Fu W et al. Ethanol Disrupts Vascular Endothelial Barrier: Implication in Cancer Metastasis. Toxicological sciences. 2012;127(1):42—53. DOI: 10.1093/toxsci/kfs087][Hunter DJ, Colditz GA, Hankinson SE et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiology. 2010;19(10):2496—2502. DOI: 10.1158/1055—9965.EPI-10-0747][Nelson HD, Tyne K, Naik A et al. Screening for breast cancer: an update for the U.S.Preventive Services Task. Annals of internal medicine. 2009;151(10):727—737. DOI: 10.7326/0003-4819-151-10-200911170-00009][Schwarz EB, Foster DG, GrossmanD. Contemporary Hormonal Contraception and the Risk of Breast Cancer. New England Journal of Medicine. N Eng J Med. 2018;378(13):1263—1264. DOI: 10.1056/NEJMc1800054][Easton DF, Pharoah PDP, Antoniou AC et al. Gene-panel sequencing and the prediction of breast-cancer risk. New England Journal of Medicine. N Eng J Med. 2015;372(23):2243—2257. DOI: 10.1056/NEJMsr1501341][Chlebowski RT, Aragaki ZK, Anderson GL. Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. Journal of the National Comprehensive Cancer Network. JNCCN. 2016;13(7):917—924. DOI: 10.6004/jnccn.2015.0106][Guffy D, Vulkan D, Cuckle H et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. The Lancet Oncology. 2020;21(9):1165—1172. DOI: 10.1016/S1470-2045(20) 30398—3][Bertsimas D, Ma Y, NohadaniO. Personalized Breast Cancer Screening. JCO Clinical Cancer Informatics. JCO Clin Cancer Inform.2023;7(7):e2300026. DOI: 10.1200/CCI.23.00026][LeVasseur N, ChiaS. Cancer screening and prevention in BRCA mutation carriers: a missed opportunity? British Journal of Cancer. 2019;121(1):1—2. DOI: 10.1038/s41416-019-0484-8][Duffy SW, Vulkan D, Cuckle H et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled. The Lancet Oncology. 2020;21(9):1165—1172. DOI: 10.1016/S1470-2045(20)30398—3][Beaber EF, Buist DSM, Barlow WE et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer research. 2014;74(15):4078—4089. DOI: 10.1158/0008—5472.CAN-13-3400][Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. The Bmj. 2009;339. DOI: 10.1136/bmj.b2587][Chen Y, James JJ, Michalopoulou E et al. Performance of Radiologists and Radiographers in Double Reading Mammograms: The UK National Health Service Breast Screening Program. Radiology. Radiology. 2023:306(1):102—109. DOI: 10.1148/radiol.212951][Porter PL, El-Bastawissi LY, Mandelson MT et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. Journal of the National Cancer Institute. JNCI. 1999;91(23):2020—2028. DOI: 10.1093/jnci/23.91.2020][Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care for the population of Russia in 2022. Moscow: P.A.Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2022 (in Russian).][Hussein H, Abbas E, Keshavarzi S et al. Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis. Radiology. 2023;306(3):e221785. DOI: 10.1148/radiol.221785][Solikhah S, Promthet S, HurtsC. Awareness Level about Breast Cancer Risk Factors, Barriers. Attitude and Breast Cancer Screening among Indonesian Women. APJCP. 2019;20(3):877. DOI: 10.31557/APJCP.2019.20.3.877][McCarthy AM, Guan Z, Welch M et al. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography cohort. Journal of the National Cancer Institute. JNCI. 2020;112(5):489—497. DOI: 10.1093/jnci/djz177][Desai P, AggarwalA. Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options. Clinics in Geriatric Medicine. 2021;37(4):611—623. DOI: 10.1016/j.cger.2021.05.007][Evans DGR, HowellA. Breast cancer risk-assessment models. Breast cancer research. 2007;9(5):1—8. DOI: 10.1186/bcr1750][Parmigiani G, BerryD., AguilarO. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. The American Journal of Human Genetics. AJHG. 1998;62(1):145—158. DOI: 10.1086/301670][Reiner AS, Sisti J, John EM et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update from the Women's Environmental Cancer and Radiation Epidemiology. Journal of clinical oncology. JCO. 2018;36(15):1513. DOI: 10.1200/JCO.2017.77.3424][Fisher S, Yasui Y, Dabbs et al. Survival in stage I—III breast cancer patients by surgical treatment in a publicly funded health care system. Annals of oncology. 2015;26(6):1161—1169. DOI: 10.1093/annonc/mdv107][Gnerlich JL, Deshpande AD, Jeffe BD et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. Journal of the American College of surgeons. JACS. 2009;208(3):341—347. DOI: 10.1016/j.jamcollsurg.2008.12.001]